

IN THE SPECIFICATION

Please **amend** paragraph [0018] with the following rewritten paragraph:

[0018] The accompanying figures illustrate the present invention. Abbreviations are used as follows:

P1° H-Lys-Phe-Met-Met-Thr-Pro-pTyr-Val-Val-Thr-Arg-NH<sub>2</sub> (SEQ ID NO:1)

P1\* H-Lys-Phe-Met-Met-pThr-Pro-Tyr-Val-Val-Thr-Arg-NH<sub>2</sub> (SEQ ID NO:2)

Q1 P1\*° H-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH<sub>2</sub> (SEQ ID NO:3)

TAMRA-P1\*° 5-TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH<sub>2</sub>  
(SEQ ID NO:4)

TAMRA 5'-(6-carboxytetramethylrhodamine)

AEEA 8-amino-3,6-dioxaoctanoic acid linker

IN THE CLAIMS

Please **amend** claim 1 with the following rewritten claim:

Q2 10. (AMENDED) The process according to claim 9, wherein the ligand comprises Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH<sub>2</sub>, and particular is 5-TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH<sub>2</sub>.